查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917878

表观遗传学诊断市场—2026-2031年预测

Epigenetic Diagnostics Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计表观遗传诊断市场在预测期（2026-2031 年）内将显着成长。

表观遗传诊断市场已成为分子诊断领域一个变革性的细分市场，其重点在于检测并非由DNA序列本身编码的可遗传基因基因表现变化。这些修饰，主要包括DNA甲基化、组蛋白修饰和非编码RNA活性，能够提供重要的生物学讯息，是基因组分析的补充。该市场的核心提案在于能够早期检测癌症等疾病，对患者进行风险分层，并预测治疗反应，从而更精准地应用精准医疗。目前，该领域正经历着从研究导向型向商业性临床平台的关键转型，其核心在于将复杂的实验室开发检测方法标准化为稳健、高通量的体外诊断（IVD）试剂盒，以便于广泛的临床应用和医保报销。

肿瘤应用领域市场领导地位的显着提升是当前的主要趋势。表观遗传失调是癌症的标誌性特征，该领域的诊断技术能够满足整个治疗过程中许多尚未满足的需求。这些需求包括：透过液态生物检体分析肿瘤特异性DNA甲基化模式进行非侵入性早期检测；利用胶质母细胞瘤中MGMT启动子甲基化等标记物进行预后分层；以及针对表观遗传路径的新兴治疗方法（例如DNA甲基转移酵素酶抑制剂）的伴随诊断。结肠癌筛检试验的临床检验和监管核准已树立了重要的先例，证明了表观遗传生物标记在标准治疗方案中的效用和整合性，从而显着推动了该领域的需求。

从技术角度来看，市场正经历着基于次世代定序（NGS）平台的根本性转变。儘管基于PCR的方法因其速度快、成本低而在靶向分析领域仍占据主导地位，但NGS凭藉其无与伦比的能力——以单碱基分辨率进行全面的全基因组表观遗传分析——正迅速获得广泛应用。这种能力对于发现新型生物标记和开发复杂的多标誌物组合至关重要。 NGS成本的下降和普及降低了进入门槛，使得在研究和临床环境中进行更高级的分析成为可能。同时，试剂盒和试剂盒细分市场占据了最大的消费份额，这表明持续的科学发现是市场的基石，而学术和生物製药研究机构对高通量表观遗传分析的持续需求则推动了这一市场的发展。

在区域层面，北美保持着领先的收入份额，这得益于一系列强有力的因素，包括雄厚的公共和私人研究经费、主要市场参与企业和创新型Start-Ups公司的高度集中，以及有利于先进诊断检测方法临床应用的法规环境。该地区各支付系统对已通过核准遗传学检测的有利覆盖和报销决策，对于将技术创新转化为商业性成功和临床效用至关重要，并为其他地区树立了榜样。

市场成长受多种相互关联的因素所驱动。慢性疾病（尤其是癌症）在全球的快速流行，使得临床上迫切需要先进的诊断工具，而表观遗传学改变正是癌症发病机制的基础。此外，针对表观遗传机制的药物研发管线日趋成熟，也直接催生了伴随诊断测试的需求，以便识别可能从治疗中获益的患者群体。然而，仍有许多挑战阻碍着这些工具的加速临床应用。主要阻碍因素包括检测方法之间缺乏标准化和可重复性，特别是针对组蛋白修饰的抗体特异性，以及检体处理过程中的技术差异。这种差异引发了临床医师对数据可靠性的担忧，也使得制定通用的临床指引变得更加复杂。

表观遗传学与其他尖端科技的融合蕴藏着巨大的未来潜力。将人工智慧（AI）和机器学习应用于分析表观遗传谱分析产生的庞大而复杂的资料集，有望揭示新型、高度特异性的疾病特征，从而提高诊断灵敏度和预后预测能力。此外，与单细胞定序技术的整合将有助于阐明组织和肿瘤内的表观遗传异质性，为理解疾病机制和开发标靶干预措施开闢新的途径，尤其是在神经病学和免疫学领域。

竞争格局的特征是大型多元化生命科学和诊断公司形成寡占。这些公司凭藉其广泛的智慧财产权组合、全球商业网路以及整合的仪器、试剂和软体解决方案，维持主导地位。竞争的重点在于优化检测的灵敏度和特异性，开发用于复杂疾病的多分析物检测组合，以及应对监管审批流程以确保临床疗效。关键企业在价值链上占据战略要地；有些企业主导次世代定序仪器和核心试剂的供应，而有些企业则专注于开发和商业化针对特定临床适应症的完整、符合监管要求的诊断解决方案。

总之，表观遗传学诊断市场正处于关键转折点，正从一个充满前景的研究领域转型为现代临床实验室医学的重要组成部分。其成长轨迹与精准肿瘤学的广泛发展以及人们对錶观遗传学在慢性疾病中作用的日益重视密不可分。成功与否取决于该行业能否克服标准化障碍，向支付方证明其清晰的临床效用和成本效益，并将表观遗传学数据与遗传和临床资讯无缝整合，从而为患者管理提供可操作的见解。技术进步，朝着更全面、更易于使用的分析平台发展，将继续成为推动这个充满活力的市场中发现和商业化的关键动力。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用洞察力，做出策略决策，在动态环境中发展新的业务流和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

您打算如何使用这份报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

5. 按产品类型分類的表观遗传学诊断市场

  • 介绍
  • 试剂
  • 成套工具
  • 酵素
  • 其他的

第六章 依方法论分類的表观遗传学诊断市场

  • 介绍
  • DNA甲基化
  • 组蛋白修饰
  • 其他的

第七章 按应用分類的表观遗传学诊断市场

  • 介绍
  • 肿瘤学
  • 非肿瘤科

第八章 依最终使用者分類的表观遗传学诊断市场

  • 介绍
  • 製药和生物技术公司
  • 学术和研究机构
  • 其他的

9. 各地区表观遗传学诊断市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十一章 公司简介

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific, Inc.
  • Element Biosciences, Inc.
  • Illumina, Inc.
  • Abcam Plc（Danaher Corporation）
  • QIAGEN
  • Merck KgaA
  • Zymo Research Corporation
  • Hologic, Inc.
  • Agilent Technologies, Inc.

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615892

The Epigenetic Diagnostics Market is projected to grow significantly during the forecast period (2026-2031).

The Epigenetic Diagnostics market is emerging as a transformative segment within molecular diagnostics, focused on detecting heritable changes in gene expression not encoded in the DNA sequence itself. These modifications, primarily DNA methylation, histone alterations, and non-coding RNA activity, provide critical biological insights that complement genomic analysis. The market's core value proposition lies in its ability to detect diseases like cancer at earlier stages, stratify patient risk, and predict therapeutic response, thereby enabling a more precise application of precision medicine. Currently, the field is undergoing a pivotal transition from a research-oriented discipline to a commercial clinical platform, with a central focus on standardizing complex laboratory-developed tests into robust, high-throughput in vitro diagnostic (IVD) kits suitable for widespread clinical adoption and reimbursement.

A dominant and defining trend is the clear market leadership of oncology applications. Epigenetic dysregulation is a well-established hallmark of cancer, and diagnostics in this segment address critical unmet needs across the care continuum. This includes non-invasive early detection through liquid biopsies analyzing tumor-specific DNA methylation patterns, prognostic stratification using markers like MGMT promoter methylation in glioblastoma, and companion diagnostics for emerging therapies targeting epigenetic pathways, such as DNA methyltransferase inhibitors. The clinical validation and regulatory approval of tests for colorectal cancer screening have set a crucial precedent, demonstrating the utility and integration of epigenetic biomarkers into standard care pathways and driving significant demand within this segment.

From a technological standpoint, the market is experiencing a fundamental shift towards Next-Generation Sequencing (NGS)-based platforms. While PCR-based methods remain prevalent for targeted analysis due to their speed and lower cost, NGS is rapidly gaining adoption for its unparalleled ability to provide comprehensive, genome-wide epigenetic profiling at single-base resolution. This capability is essential for discovering novel biomarkers and developing complex multi-marker panels. The declining cost and increased accessibility of NGS are lowering barriers to entry and enabling more sophisticated analyses in both research and clinical settings. Concurrently, the Reagents and Kits product segment represents the highest volume consumption, fueled by persistent demand from academic and biopharmaceutical research institutes conducting high-throughput epigenetic profiling, underscoring the market's foundation in ongoing scientific discovery.

Geographically, North America maintains a leading revenue share, driven by a confluence of powerful factors. These include robust public and private research funding, a high concentration of key market participants and innovative startups, and a regulatory environment that has facilitated the clinical adoption of sophisticated diagnostic assays. Favorable coverage and reimbursement decisions for approved epigenetic tests within the region's payer systems have been instrumental in translating technological innovation into commercial success and clinical utility, creating a model for other regions.

The market's growth is propelled by several interconnected drivers. The accelerating global prevalence of chronic diseases, particularly cancers where epigenetic alterations are fundamental to pathogenesis, creates a pressing clinical need for advanced diagnostic tools. Furthermore, the maturation of drug pipelines targeting epigenetic mechanisms directly generates demand for companion diagnostic assays to identify patient populations most likely to respond. However, significant challenges impede faster clinical adoption. A primary restraint is the lack of standardization and reproducibility across assays, especially concerning antibody specificity for histone modifications and the technical variability in sample processing. This variability creates data reliability concerns among clinicians and complicates the establishment of universal clinical guidelines.

Significant future opportunity lies in the integration of epigenetics with other cutting-edge technologies. The application of Artificial Intelligence and machine learning to analyze the vast, complex datasets generated by epigenetic profiling holds promise for uncovering novel, highly specific disease signatures with improved diagnostic sensitivity and prognostic power. Additionally, the convergence with single-cell sequencing technologies allows for the dissection of epigenetic heterogeneity within tissues and tumors, opening new avenues for understanding disease mechanisms and developing targeted interventions, particularly in neurology and immunology.

The competitive landscape is characterized by an oligopolistic structure dominated by large, diversified life science and diagnostic corporations. These players leverage extensive IP portfolios, global commercial networks, and integrated offerings of instruments, reagents, and software to maintain leadership. Competition centers on optimizing assay sensitivity and specificity, developing multi-analyte panels for complex diseases, and navigating the regulatory pathways to secure clinical claims. Key players are strategically positioned across the value chain: some dominate as suppliers of essential NGS instrumentation and core reagent chemistries, while others focus on developing and commercializing complete, regulated diagnostic solutions for specific clinical indications.

In conclusion, the Epigenetic Diagnostics market is poised at a critical juncture, transitioning from a promising research field to an essential component of modern laboratory medicine. Its growth trajectory is inextricably linked to the broader expansion of precision oncology and the increasing recognition of epigenetics' role in chronic disease. Success will be determined by the industry's ability to overcome standardization hurdles, demonstrate clear clinical utility and cost-effectiveness to payers, and seamlessly integrate epigenetic data with genetic and clinical information to provide actionable insights for patient management. The ongoing technological evolution towards more comprehensive and accessible analysis platforms will continue to be the primary engine for discovery and commercialization in this dynamic market.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Epigenetics Diagnostics Market Segmentation

  • By Product Type
  • Reagents
  • Kits
  • Enzymes
  • Others
  • By Method
  • DNA Methylation
  • Histone Modification
  • Others
  • By Application
  • Oncology
  • Non-Oncology
  • By End-User
  • Pharmaceutical & Biotec Companies
  • Academic & Research Institutes
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. EPIGENETICS DIAGNOSTICS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Reagents
  • 5.3. Kits
  • 5.4. Enzymes
  • 5.5. Others

6. EPIGENETICS DIAGNOSTICS MARKET BY METHOD

  • 6.1. Introduction
  • 6.2. DNA Methylation
  • 6.3. Histone Modification
  • 6.4. Others

7. EPIGENETICS DIAGNOSTICS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Oncology
  • 7.3. Non-Oncology

8. EPIGENETICS DIAGNOSTICS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Pharmaceutical & Biotec Companies
  • 8.3. Academic & Research Institutes
  • 8.4. Others

9. EPIGENETICS DIAGNOSTICS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. F. Hoffmann-La Roche Ltd
  • 11.2. Thermo Fisher Scientific, Inc.
  • 11.3. Element Biosciences, Inc.
  • 11.4. Illumina, Inc.
  • 11.5. Abcam Plc (Danaher Corporation)
  • 11.6. QIAGEN
  • 11.7. Merck KgaA
  • 11.8. Zymo Research Corporation
  • 11.9. Hologic, Inc.
  • 11.10. Agilent Technologies, Inc.

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations